Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for HER2-low and HER2-ultralow metastatic breast cancer, drawn from the whole corpus: 11 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Immunohistochemistry was never designed to score low expression and pathologists disagree at the 0 to 1+ boundary.
Whether a second topoisomerase I payload works after the first.
Interstitial lung disease remains unpredictable.
The triple-negative HER2-low group has only exploratory randomised data.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 11 changes by month →When this page itself was last checked or edited.
OS 23.
PFS HR 0.
A milestone in how this cancer is treated.
A milestone in how this cancer is treated.
OS HR 0.